1. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer;Martini A;Cancer,2019
2. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Oncology Center of Excellence.Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed June 18 2019.
3. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman HB;N Engl J Med,2003
4. Chemotherapy for bladder cancer;Munoz A;N Engl J Med,2003
5. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma;Logothetis C;J Urol,1996